PPARG and Insulin resistance: The clinical efficacy of Pioglitazone in our patient could not be explained by the decrease in insulin resistance alone, but might be related to molecular interaction between Pioglitazone and the mutant PPARγ gene, at least in this case of a c.1024C>T variant.